Aplastic anemia: pathogenesis and treatment.
Treatment of severe aplastic anemia (SAA) in Europe between 1970 and 1986 is reviewed. 487 patients received an HLA-identical BMT: results are encouraging and currently suggest a 65% survival. However, many patients cannot be offered this procedure because of the absence of an appropriate donor. Forty-five patients were given a non-HLA identical BMT: results are dependent on the degree of mismatch. Immunosuppression (IS) was given to 509 patients: 50% of these survive. Some mechanisms regulating in vitro hematopoiesis are discussed, together with their relevance in the treatment of SAA.
Bacigalupo
A
A
Piaggio
G
G
Van Lint
M T
MT
Figari
O
O
Marmont
A
A
Congiu
M
M
D000741:Anemia, Aplastic / Q000097:blood / Q000276:immunology / Q000628:therapy*; D016026:Bone Marrow Transplantation; D005838:Genotype; D006085:Graft Survival; D006680:HLA Antigens / Q000235:genetics; D006410:Hematopoiesis; D006801:Humans; D007165:Immunosuppression Therapy; D007167:Immunotherapy
D006680:HLA Antigens